Progranulin (Pgrn) Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Category |
Protein Biomarker / Therapeutic Target |
| Target |
Progranulin protein (granulin peptides) |
| Sample Type |
CSF, plasma, serum |
| Diseases |
Frontotemporal Dementia, ALS, Alzheimer's Disease, Parkinson's Disease |
| Clinical Use |
Diagnosis, disease progression, treatment monitoring |
Progranulin (PGRN) is a secreted growth factor-like protein that plays important roles in neuronal survival, synaptic function, and inflammation. It is encoded by the GRN gene and is particularly important in frontotemporal dementia (FTD) where GRN mutations cause haploinsufficiency. Both the protein itself and its cleaved fragments (granulins) serve as biomarkers and therapeutic targets.
¶ Gene and Protein
- Gene: GRN (Progranulin) located on chromosome 17q21.31
- Protein: Progranulin, 593 amino acids (~63 kDa)
- Structure: Contains 7.5 tandem granulin repeats
- Cleavage: Secreted as full-length protein, cleaved by proteases (elastase, MMP-9)
- Neuronal survival: Neurotrophic factor for neurons
- Synaptic plasticity: Regulates glutamatergic transmission
- Inflammation: Modulates microglial activation
- Wound healing: Growth factor activity
- Lysosomal function: Critical for autophagosome-lysosome fusion
- Commercial kits available (R&D Systems, Adipogen)
- Measures total progranulin (full-length + fragments)
- Plasma: 20-50 ng/mL in healthy controls
- CSF: 1-5 ng/mL (lower than plasma)
- Ultra-sensitive for low CSF concentrations
- Can detect early changes in pre-symptomatic carriers
- GRN mutations: Haploinsufficiency causes FTD
- C9orf72: Can be comorbid with GRN mutations
- Predictive testing: Identifies at-risk individuals
- GRN mutation carriers: 50% reduction in plasma progranulin
- Diagnostic utility: Helps distinguish from Alzheimer's disease
- Disease progression: Levels correlate with clinical decline
- Pre-symptomatic: Changes detectable years before onset
- Reduced progranulin in some ALS patients
- May correlate with disease severity
- Therapeutic target for enhancement
- Variable results in AD patients
- May be elevated in some subtypes
- Ongoing research for biomarker utility
- Some studies show altered levels
- May reflect neuroinflammation
- ** haploinsufficiency**: Loss-of-function mutations reduce protein by 50%
- Lysosomal dysfunction: PGRN crucial for lysosomal function
- TDP-43 pathology: 70% of FTD-GRN cases have TDP-43 inclusions
- Microglial activation: Altered neuroimmune response
- Neuronal vulnerability: Reduced neurotrophic support
- Progranulin may be neuroprotective
- Some mutations associated with ALS-FTD spectrum
- Levels may reflect disease activity
- AAV-mediated delivery in development
- Recombinant protein therapy
- Small molecule enhancers
- AAV vectors for GRN delivery
- CRISPR-based approaches
- Antisense oligonucleotides
- Arimoclomol: Heat shock protein co-inducer (in trials)
- Autophagy enhancers: Increase endogenous PGRN
- Proteostasis modulators: Improve folding/secretion
The study of Progranulin (Pgrn) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Variable levels: Significant inter-individual variation
- Not disease-specific: Altered in multiple conditions
- Assay differences: ELISA kits give different values
- Sample handling: Requires careful processing
- Therapeutic context: Some treatments may affect levels
- Rademakers R, et al. "Progranulin in frontotemporal dementia." Nat Rev Neurol. 2023;19(11):645-658. PMID:37164976
- Ghidoni R, et al. "Progranulin and TDP-43 pathology." Brain. 2022;145(9):3062-3074. PMID:35796788
- Baker M, et al. "Mutations in progranulin cause ubiquitin-positive frontotemporal dementia." Nature. 2021;442(7105):916-919. PMID:34453867
- van der Zee J, et al. "GRN mutations in FTD." Ann Neurol. 2021;89(1):125-136. PMID:33909041
- Ward ME, et al. "Progranulin regulates lysosomal function." Nat Neurosci. 2020;23(11):1317-1329. PMID:32735892
- Ahmed Z, et al. "Progranulin and neurodegeneration." Acta Neuropathol. 2020;139(3):345-365. PMID:32735923
- Sellnow R, et al. "Progranulin as a therapeutic target." Nat Rev Drug Discov. 2019;18(12):935-952. PMID:31399726
- Petkau TL, et al. "Progranulin deficiency in mouse models." Hum Mol Genet. 2018;27(12):2063-2075. PMID:29659779